No Data
Individual investor, Yugetsu Yuken: The focus on australian small/mid cap stocks is reviving, drawing even more attention to biotech stocks! [FISCO Social Reporter]
The following is a comment written by individual investor "Yuugentei Tamaki" (Blog: Profitable Stock Information "The Cat's Husband's Ceilingless Stock") of the FISCO Social Reporter. At FISCO, we strive to collaborate with individuals who actively disseminate information in order to provide a wider range of information to investors. ----------- * After the news that the Ministry of Economy, Trade and Industry will compile an action plan to expand the biotechnology industry on September 2, 2024 at 13:00, biotech stocks have a wide range of
Material Group, Chordia Therapeutics, etc.
<156A> Material Group Co., Ltd., Nomura Securities Co., Ltd. Shareholding Ratio: -% → 5.01% Obligation to Report: August 30, 2024 <190A> Chordia Therapeutics Co., Ltd., SBI Investment Co., Ltd. Shareholding Ratio: 8.73% → 6.63% Obligation to Report: July 23, 2024 <3063> J Group Holdings Co., Ltd., Tokai Tokyo Securities Co., Ltd. Shareholding Ratio:
Insider holds 5.14% of shares in Chordia Therapeutics(190A.JP)
On Sep 4, 東京大学協創プラットフォーム開発株式会社 submitted the Large Shareholding Report to Ministry of Finance to disclose its 5.14% ownership of the shares in $Chordia Therapeutics(190A.JP)$. Source: Edinet
There is a possibility that there will be a temporary pause in the market, and individual stock selection may become stronger due to positive investor sentiment.
■ The sluggish growth in trading value is a concern. This week's emerging markets are likely to experience a pause in the rebound. In the main board market, the Nikkei average is facing resistance at the 38,000 yen level. This level has a high volume of trading activity in different price ranges, indicating significant selling pressure on the rebound. The Growth Market 250 index has returned to its level before the sharp drop on August 1st, indicating that the emerging markets, like the main board market, are prone to selling pressure on the rebound. The trading value is slightly over 100 billion yen, and the trading activity is not significant.
Emerging market outlook: Will the Growth Market 250 Index take a break and individual stock picking strengthen with positive investor sentiment?
■ The emerging market this week has seen a significant increase in overall market conditions, with major stocks showing strength. During the same period, while the Nikkei Average increased by +0.79%, the Growth Market Index rose by +4.63% and the Growth Market 250 Index rose by +5.16%, highlighting the growth of the emerging market. Similar to the main board, trading volume has not expanded significantly, but driven by improved investor sentiment, major stocks with large market capitalization, such as constituents of the Growth Market Core Index, have shown overall strength. The Growth Market 250 Index opened on August 1st.
List of stocks with maximum daily price increase or decrease during the morning session.
■Top Gainer: Veritas In Silico <190A>, Chordia Therapeutics <206A>, PRISM BioLab <2170>, Link and Motivation <2767>, Tsuburaya Fields Holdings <3260>, Espo <3551>, Dynic <3667>, Enish <3739>, Comseed <3798>, ULS Group <4575>, Canvas <4893>, Noel Immune Biotech.
No Data
